<DOC>
	<DOCNO>NCT00533429</DOCNO>
	<brief_summary>The purpose study determine Pemetrexed plus Carboplatin plus Bevacizumab plus Enzastaurin , follow maintenance Bevacizumab plus Enzastaurin extend survival time without disease progression first-line treatment patient advanced stage non-small cell lung cancer .</brief_summary>
	<brief_title>Study Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo Patients With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>legal representative must sign informed consent document clinical research laboratory confirm diagnosis advance , nonsquamous cell NSCLC ( Stage IIIB IV disease ) curable receive prior systemic chemotherapy , immunotherapy , target therapy , biological therapy advance NSCLC , prior radiation therapy allow less 25 % bone marrow measurable disease adequate organ function estimate life expectancy 12 week know CNS disease ; major surgery within 28 day ; minor surgery within 7 day ; serious concommitant systemic disorder ; serious cardiac condition ; serious , nonhealing wound , ulcer , bone fracture receive treatment within last 30 day drug receive regulatory approval indication time study entry previously receive treatment enzastaurin , pemetrexed , bevacizumab pregnant breastfeeding unable swallow tablet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>